Journal
BIORESOURCE TECHNOLOGY
Volume 102, Issue 3, Pages 3649-3652Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biortech.2010.11.104
Keywords
Diketoreductase; Biocatalysis; Biphasic system; Statin drugs
Funding
- Ministry of Education of China
- State Administration of Foreign Expert Affairs of China [111-2-07]
- Jiangsu Department of Science and Technology [SBE200900234]
- National Key Project of Scientific and Technology of China [2009ZX09501-016]
Ask authors/readers for more resources
Diketoreductase from Acinetobacter baylyi ATCC 33305 is a unique carbonyl reductase, which can stereselectively reduce ethyl-6-(benzyloxy)-3,5-dioxohexanoate to ethyl 3R,5 S-6-(benzyloxy)-3,5-dihydroxy-hexanoate, an advanced intermediate for statin drugs. In the present study, we explored an aqueous-organic biphasic reaction system to make this biocatalyst more practical and valuable. Different from most oxidoreductases, diketoreductase displayed an excellent tolerance to certain organic solvents without any changes on the catalytic properties. After optimizing reaction conditions, an aqueous-hexane (1:1) biphasic system was established for the preparation of 3R,5S-dihydroxy product by diketoreductase. This system was further scaled up to 0.51 at a substrate concentration of 105 g/l (378 mM), and the 3R,5S-hydroxy product was obtained with a yield of 83.5% and excellent stereoselectivity (de > 99.5%, ee > 99.5%). (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available